5:30 PM
Oct 11, 2012
 |  BC Extra  |  Financial News

Aeterna planning follow-on

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) said late Thursday it is planning a follow-on underwritten by Roth Capital Partners. Aeterna is conducting Phase III testing of perifosine in multiple myeloma (MM). The product is a...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >